BioCentury
ARTICLE | Emerging Company Profile

Bispecific simplicity

How EpimAb improves potency, stability and immunogenicity of bispecifics

February 4, 2017 1:02 AM UTC

EpimAb Biotherapeutics Inc. is developing bispecific antibodies designed to be more potent and stable, less immunogenic and easier to manufacture than those made by competing platforms.

The company’s Fabs-In-Tandem Immunoglobulin (FIT-Ig) technology retains all four Fab domains of the parent mAbs and uses a full-length wild-type human Fc domain with no mutations or linker chemistry...

BCIQ Company Profiles

EpimAb Biotherapeutics Inc.